stockportfolio.pro
Stocks / MBX vs SRPT
MBX vs SRPT
MBX Biosciences, Inc. and Sarepta Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| MBX Biosciences, Inc. (MBX) | Sarepta Therapeutics, Inc. (SRPT) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $0 | $2.20B |
| Net income (latest FY) | $-86.97M | $-713.41M |
| Revenue growth (5y CAGR) | — | 32.4% |
| Net margin | — | -32.5% |
| Return on equity | -23.6% | -62.5% |
| P/E ratio | — | 43.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MBX — free Open SRPT — freeFrequently asked questions
Which is bigger, MBX or SRPT?
Sarepta Therapeutics, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, MBX or SRPT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.